Novo Nordisk A/S (NYSE:NVO) Shares Unloaded by Rep. Kevin Hern

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Novo Nordisk A/S (NYSE:NVO). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $1,001 and $15,000 in Novo Nordisk A/S stock on September 10th. The trade occurred in the Representative’s “KEVIN HERN TRADITIONAL IRA” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of CenterPoint Energy (NYSE:CNP) on 9/15/2026.
• Sold $1,001 – $15,000 in shares of TJX Companies (NYSE:TJX) on 9/15/2026.
• Sold $15,001 – $50,000 in shares of STERIS (NYSE:STE) on 9/15/2026.
• Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 9/15/2026.
• Sold $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of IQVIA (NYSE:IQV) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of Emerson Electric (NYSE:EMR) on 9/14/2026.

Novo Nordisk A/S Stock Performance

Shares of NYSE:NVO opened at $38.69 on Tuesday. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $64.16. The company’s 50 day moving average price is $45.51 and its two-hundred day moving average price is $43.87. The firm has a market cap of $172.77 billion, a PE ratio of 9.46, a PEG ratio of 1.27 and a beta of 0.74. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. The business had revenue of $11.98 billion during the quarter. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%. Equities research analysts predict that Novo Nordisk A/S will post 3.54 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a dividend, which was paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th were given a dividend of $0.5786 per share. This represents a dividend yield of 258.0%. The ex-dividend date was Monday, August 17th. This is a drop from Novo Nordisk A/S’s previous dividend of $1.2751. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 20.05%.

Institutional Investors Weigh In On Novo Nordisk A/S

Several hedge funds and other institutional investors have recently made changes to their positions in NVO. Arrowstreet Capital Limited Partnership bought a new stake in Novo Nordisk A/S in the first quarter valued at $287,660,000. Maverick Capital Ltd. acquired a new stake in shares of Novo Nordisk A/S in the 1st quarter valued at about $76,444,000. Contrarius Group Holdings Ltd acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at about $47,337,000. Public Employees Retirement System of Ohio acquired a new position in Novo Nordisk A/S during the 1st quarter worth approximately $27,802,000. Finally, Franklin Resources Inc. boosted its holdings in Novo Nordisk A/S by 5.1% in the fourth quarter. Franklin Resources Inc. now owns 14,702,508 shares of the company’s stock worth $748,064,000 after acquiring an additional 717,719 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Berenberg Bank set a $47.00 price target on Novo Nordisk A/S in a research report on Wednesday, August 12th. Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. Weiss Ratings raised shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. Finally, BMO Capital Markets reissued a “market perform” rating and issued a $47.00 price objective on shares of Novo Nordisk A/S in a research note on Thursday, August 6th. Three equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $64.94.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk agreed to license global rights to Hengrui Pharma’s HRS-1596, an experimental once-weekly oral GLP-1/GIP dual agonist for obesity and type 2 diabetes. The agreement includes $300 million upfront and up to $2.6 billion in total payments, plus royalties, giving Novo another potential oral obesity treatment. However, HRS-1596 is only phase 1-ready, so commercial benefits are years away. China’s Hengrui inks up to $2.6 billion deal with Novo Nordisk for obesity drug
• Positive Sentiment: Phase 3 REIMAGINE 5 data showed the 1 mg/1 mg CagriSema dose produced an estimated 12.4% average weight loss after 60 weeks in adults with type 2 diabetes. The result strengthens the case for CagriSema as a competitive next-generation obesity product and supports hopes for a recovery in Novo’s core franchise. Novo Nordisk Just Beat Lilly in a Trial
• Positive Sentiment: Novo is expanding its future dosing options through an exclusive collaboration with Nanexa. Its PharmaShell delivery technology will support as many as five programs targeting obesity, diabetes and other cardiometabolic conditions, potentially enabling longer-acting or monthly treatments. Novo Nordisk Licenses Nanexa’s PharmaShell
• Neutral Sentiment: Novo’s ongoing share-repurchase program, part of a plan worth up to DKK 15 billion over 12 months, may provide technical support and signal management confidence, but it does not resolve concerns about future earnings growth. Novo Nordisk A/S share repurchase programme
• Negative Sentiment: Competitive pressure remains intense. Roche reported 15.5% weight loss in a mid-stage trial, while Eli Lilly continues to strengthen its position in the U.S. GLP-1 market. Investors are also questioning what will replace Novo’s current obesity-drug growth as its shares remain far below their prior peak. Roche’s Latest Obesity Drug Results

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Novo Nordisk A/S

Novo Nordisk A/S is a Denmark-based global pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes injectable and oral medicines for diabetes, including insulin products and the GLP-1 therapies Ozempic and Rybelsus, as well as the obesity treatment Wegovy.

The company also develops and markets products for rare blood disorders, including hemophilia, along with growth hormone therapies and hormone replacement treatments.